Sanofi (SNY) Announces Financial Results for Q1 2026
Sanofi (NASDAQ:SNY) is one of the best stem cell therapy stocks to buy.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 11,442,163 | $551,283,461 | -6% | 0.19% |
| 2. | Arjuna Capital Farnum Brown And Adam Seitchik | 57,028 | $2,747,610 | +2% | 0.7% |
| 3. | Pzena Investment Management Richard S. Pzena | 19,088 | $919,636 | +63% | 0% |
| 4. | Leucadia National Ian Cumming And Joseph Steinberg | 12,363 | $595,649 | +27% | 0% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,040,065 | $242,830,335 | 3.63% | |
| 2. | 3,861,894 | $186,066,032 | 0.05% | |
| 3. | 2,663,054 | $128,305,962 | 2.51% | |
| 4. | 2,206,237 | $106,296,512 | 0.03% | |
| 5. | 2,094,962 | $100,165,953 | 0.54% |